Tests BMS-986488 alone or combined in adults with advanced cancers
Tests BMS-986488, alone or with other drugs, in adults with advanced cancers.
Plain-language title generated from the registry record
Registry title: A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Key facts
- Where
- Brisbane, AustraliaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced solid tumours that cannot be removed by surgery or have spread. It tests BMS-986488 alone or with other drugs.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Locally advanced tumour that cannot be removed by surgery, or tumour that has spread (metastatic). Tumour types depend on the study part: clear-cell kidney cancer, clear-cell ovarian cancer, non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma. Some parts need a KRAS G12C mutation. Disease must be measurable (RECIST v1.1).
- Biomarker or test result
- KRAS G12C mutation is needed in some parts of the trial (solid tumours, non-small cell lung cancer, colorectal cancer).
Main reasons for not taking part
- Untreated brain or spinal cord (CNS) metastases
- Leptomeningeal metastasis (carcinomatous meningitis)
- Impaired heart function or significant heart disease
- For adagrasib combination parts: past pneumonitis or interstitial lung disease
- For adagrasib combination parts: past severe skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis
Read by machine on 12 November 2026.
Where in Australia
- Brisbane, QueenslandHospital not named in the registryNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06764771
- Record updated
- 29 July 2026
- Original description
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.Read full original descriptionShow less
A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
Inclusion: Participant must be ≥ 18 years of age; Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:; Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC); Parts 2A, 1D, 2D: ccRCC; Part 1B: solid tumors with KRAS G12C mutation; Part 2B: NSCLC with KRAS G12C mutation; Parts 1C, 2C: colorectal cancer (CRC) with KRAS G12C mutation; Participants must have an Eastern Cooperative Oncology Groups (ECOG) Performance Status of 0 or 1; Participants must have measurable disease per RECIST v1.1.
Exclusion: History of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN); Impaired cardiac function or clinically significant cardiac disease; For Parts 1B, 1C, 2B, 2C only (combination with adagrasib):; History of pneumonitis or interstitial lung disease (ILD); Untreated central nervous system (CNS) metastases; Leptomeningeal metastasis (carcinomatous meningitis); Other protocol-defined inclusion/exclusion criteria apply.